A RESTROSPECTIVE NON-INTERVENTIONAL STUDY AMONG PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS SWITCHING TO FINGOLIMOD OR TO OTHER DISEASE MODIFYING THERAPIES

被引：0
|
作者：
Medin, J. [1 ]
Haddad, P. [2 ]
Ricart, J. [3 ]
Lara, N. [4 ]
Pedros, M. [4 ]
Bizouard, G. [5 ]
Loefroth, E. [1 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[3] Novartis Farmaceut SA, Barcelona, Spain
[4] IMS Hlth, Barcelona, Spain
[5] IMS Hlth RWE, Boulogne Billancourt, France
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.465
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND12
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [41] Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
    Samjoo, Imtiaz A.
    Worthington, Evelyn
    Drudge, Christopher
    Zhao, Melody
    Cameron, Chris
    Haering, Dieter A.
    Stoneman, Dee
    Klotz, Luisa
    Adlard, Nicholas
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (18) : 1255 - 1274
  • [42] Efficacy of Natalizumab after Insufficient Response to Other Disease Modifying Therapies for the Treatment of Relapsing Remitting Multiple Sclerosis
    Putzki, Norman
    NEUROLOGY, 2010, 74 (09) : A553 - A553
  • [43] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    PLOS ONE, 2017, 12 (10):
  • [44] REALMS study: a non-interventional retrospective, multicenter study to evaluate the effectiveness of fingolimod therapy in real-life clinical practice in patients with relapsing-remitting multiple sclerosis (RRMS) in Portugal
    Batista, S.
    Nunes, C. C.
    Mendonca, M. T.
    Sa, J.
    Correia, A. S.
    Sequeira, J.
    Salgado, V.
    Cerqueira, J.
    Pinheiro, J.
    Silva, A. M.
    Sousa, L.
    Costa, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 950 - 950
  • [45] Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients
    Lescot, Lucile
    Lefort, Mathilde
    Leguy, Soizic
    Le Page, Emmanuelle
    Vukusic, Sandra
    Edan, Gilles
    Kerbrat, Anne
    Lebrun-Frenay, Christine
    De Seze, Jerome
    Laplaud, David Axel
    Wiertlewski, Sandrine
    Leray, Emmanuelle
    Michel, Laure
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [46] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
  • [47] COMPARING THE TOTAL COSTS OF ORAL DISEASE MODIFYING THERAPIES FOR PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS IN THE US
    Le, H. H.
    Pelligra, C.
    Coughlan, A.
    Keenan, A.
    VALUE IN HEALTH, 2022, 25 (01) : S75 - S75
  • [48] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [49] Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
    Kim, Su-Hyun
    Park, Min Su
    Kim, Woojun
    Huh, So-Young
    Shin, Hyun-June
    Hyun, Jae-Won
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2019, 15 (01): : 20 - 26
  • [50] Adherence to disease-modifying therapies among patients with multiple sclerosis in Bulgaria - A real world study
    Seitaridou, Yoana
    Chamova, Teodora
    Kamusheva, Maria
    PHARMACIA, 2024, 71 : 1 - 7
12345